by TractManager | Mar 31, 2021 | News
The Food and Drug Administration (FDA) has issued the following safety alerts:Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast ReconstructionThe FDA is informing patients, caregivers, and health care providers that certain acellular dermal matrix...
by TractManager | Mar 31, 2021 | Emerging Technology Report
The Portable Neuromodulation Stimulator (PoNS) device is a portable neuromodulation stimulator for short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis for use by prescription only as an adjunct to a supervised therapeutic...
by TractManager | Mar 30, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).Technology Description: Aquablation therapy is a minimally invasive procedure that ablates overgrown...
by TractManager | Mar 29, 2021 | Emerging Technology Report
Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy,...
by TractManager | Mar 26, 2021 | News
These Food and Drug Administration (FDA) developments recently came in:Recall: Telmisartan TabletsAlembic Pharmaceuticals Inc. is voluntarily recalling 1 lot of telmisartan tablets, 20 mg, packaged in 30-count bottles. The product is being recalled due to a market...
Recent Comments